6-[Bis(carboxymethyl)amino]-1，4-bis(carboxymethyl)-6-methyl-1，4-diazepane (AAZTA ) is a promising chelator with potential advantages over 1，4，7，10-tetraazacyclododecane-1，4，7，10-tetraacetic acid (DOTA) for radiopharmaceutical applications. Its mesocyclic structure enables fast radiolabelling under mild conditions with trivalent metals including not only (68)Ga for positron emission tomography (PET) but also (177)Lu and (111)In for single-photon emission computed tomography (SPECT) and radionuclide therapy. Here， we describe the evaluation of a bifunctional AAZTA derivative conjugated to a model minigastrin derivative as a potential theranostic agent.
6-[Bis(carboxymethyl)amino]-1，4-bis(carboxymethyl)-6-methyl-1，4-diazepane (AAZTA ) is a promising chelator with potential advantages over 1，4，7，10-tetraazacyclododecane-1，4，7，10-tetraacetic acid (DOTA) for radiopharmaceutical applications. Its mesocyclic structure enables fast radiolabelling under mild conditions with trivalent metals including not only (68)Ga for positron emission tomography (PET) but also (177)Lu and (111)In for single-photon emission computed tomography (SPECT) and radionuclide therapy. Here， we describe the evaluation of a bifunctional AAZTA derivative conjugated to a model minigastrin derivative as a potential theranostic agent.
